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It is judged safe to discontinue treatment with tyrosine kinase inhibitors(TKI) for chronic myeloid leukemia (CML) in experimental trials ontreatment-free remission (TFR). We collected a total of 293 Italian
patients with chronic phase CML who discontinued TKI in deep molecular
response. Seventy-two percent of patients were on treatment with ima-
tinib, and 28% with second generation TKI at the time of discontinuation.
Median duration of treatment with the last TKI was 77 months
[Interquartile Range (IQR) 54;111], median duration of deep molecular
response was 46 months (IQR 31;74). Duration of treatment with TKI and
duration of deep molecular response were shorter with second generation
TKI than with imatinib (P<0.001). Eighty-eight percent of patients discon-
tinued as per clinical practice, and reasons for stopping treatment were: tox-
icity (20%), pregnancy (6%), and shared decision between treating physi-
cian and patient (62%). After a median follow up of 34 months (range, 12-
Observational study of chronic myeloid
leukemia Italian patients who discontinued
tyrosine kinase inhibitors in clinical practice
Carmen Fava,1 Giovanna Rege-Cambrin,1 Irene Dogliotti,1 Marco Cerrano,2
Paola Berchialla,1 Matteo Dragani,1 Gianantonio Rosti,3 Fausto Castagnetti,3
Gabriele Gugliotta,3 Bruno Martino,4 Carlo Gambacorti-Passerini,5
Elisabetta Abruzzese,6 Chiara Elena,7 Patrizia Pregno,8 Antonella Gozzini,9
Isabella Capodanno,10 Micaela Bergamaschi,11 Monica Crugnola,12 Monica
Bocchia,13 Sara Galimberti,14 Davide Rapezzi,15 Alessandra Iurlo,16 Daniele
Cattaneo,16 Roberto Latagliata,17 Massimo Breccia,17 Michele Cedrone,18
Marco Santoro,19 Mario Annunziata,20 Luciano Levato,21 Fabio Stagno,22
Francesco Cavazzini,23 Nicola Sgherza,24 Valentina Giai,25 Luigia Luciano,26
Sabina Russo,27 Pellegrino Musto,28 Giovanni Caocci,29 Federica Sorà,30
Francesco Iuliano,31 Francesca Lunghi,32 Giorgina Specchia,33 Fabrizio Pane,26
Dario Ferrero,2 Michele Baccarani3 and Giuseppe Saglio1
1Department of Clinical and Biological Sciences, University of Turin, Orbassano;
2Hematology Division, Department of Molecular Biotechnologies and Health Sciences,
University of Turin, Turin; 3Institute of Hematology "L. & A. Seràgnoli", St. Orsola University
Hospital, Bologna; 4Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria;
5University Milano Bicocca, San Gerardo Hospital, Monza; 6Haematology Unit, S. Eugenio
Hospital, Rome; 7Hematology Hunit, Fondazione IRCCS Policlinico San Matteo, Pavia; 
8A.O. Città della Salute e della Scienza di Torino, Turin; 9SC Terapie Cellulari e Medicina
Trasfusionale, AOU Careggi, Florence; 10Hematology, Azienda Unità Sanitaria Locale -
IRCCS, Reggio Emilia; 11Division of Hematology 1, IRCCS AOU San Martino-IST, Genoa;
12Division of Hematology, University Hospital of Parma, Parma; 13Azienda Ospedaliera
Universitaria, University of Siena, Siena; 14Hematology Department, University of Pisa,
Pisa; 15S.C. Ematologia, ASO S. Croce e Carle, Cuneo; 16Haematology Division, Foundation
IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 17Department of Cellular
Biotechnologies and Hematology, University La Sapienza, Rome; 18UOC of Hematology, 
San Giovanni - Addolorata Hospital, Rome; 19Hematology Unit, University of Palermo,
Palermo; 20Division of Hematology, Ospedale Cardarelli, Naples; 21Department
Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro; 22Chair and
Hematology Section, Ferrarotto Hospital, Catania; 23Department of Medical Sciences -
Haematology and Physiopathology of Haemostasis Section, Ferrara; 24Division of
Hematology, IRCCS Ospedale Casa Sollievo Sofferenza, San Giovanni Rotondo; 25Division
of Haematology, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria; 26Division of
Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico
II, Naples; 27Department of Internal Medicine, AOU Policlinico di Messina, Messina;
28IRCCS, Centro Di Riferimento Oncologico Della Basilicata, Rionero in Vulture;
29Department of Medical Sciences, University of Cagliari, Cagliari; 30Hematology
Department, University Cattolica del Sacro Cuore - Policlinico A. Gemelli, Rome; 31Presidio
Ospedaliero N. Giannetasio - Azienda ASL 3, Rossano; 32Division of Haematology and
Bone Marrow Transplant, Ospedale San Raffaele IRCCS, Milan and 33Division of
Haematology with Transplant – Outpatients, Azienda Ospedaliero-Universitaria Policlinico
Consorziale di Bari, Bari, Italy
ABSTRACT
Introduction 
Chronic myeloid leukemia (CML) patients have reached
a near-normal life expectancy thanks to tyrosine kinase
inhibitors (TKI).1,2 These drugs, however, can cause several
persistent low-grade side effects that affect quality of life,
and can be associated in the long term with severe toxici-
ties.3 For this lifelong  disease, tolerance and adherence to
treatment are an issue. Furthermore, thanks to the success
of the therapies, patients grow older and accumulate
comorbidities that require concomitant treatments that
can  possibly interfer with TKI. Younger patients have
other problems because living with TKI interferes with
family planning,  availability for the job market, life insur-
ance, and so on.4 Besides, as more and more patients are
living with their disease, high treatment costs are becom-
ing an important issue.5
Over recent years, several papers have reported on treat-
ment discontinuation in CML patients in persistent deep
molecular response (DMR).6-25 The majority of these stud-
ies have reported on patients who had achieved a DMR
with imatinib. There are fewer data reported on the dis-
continuation of second generation TKI, and with a shorter
follow up. The definitions of DMR and the criteria for
treatment discontinuation, for molecular relapse, and for
treatment resumption, varied among these studies.
Therefore, the reported treatment-free remission (TFR)
rate ranged widely (between 30% and 70%), with the first
reports mostly showing a TFR rate of approximately 40%;
more recent reports, which adopted less stringent criteria
for treatment discontinuation and therapy resumption,
showed a TFR rate of approximately 60%. Partly due to
these different definitions, it is still difficult to identify the
factors that may predict for the TFR rate, although some
analyses have drawn attention to the predictive value of
treatment duration, Sokal score, duration of molecular
response (MR), and response to first-line TKI treatment.
Prior studies were mostly academic or company-spon-
sored; these were mostly prospective in nature, with
restricted and carefully selected inclusion criteria.
Nowadays, doctors and patients are willing and ready to
introduce TKI discontinuation in clinical practice. Very
few data are available on the effects and the outcome of
treatment discontinuation outside prospective studies and
without a central control of MR. We report here on 293
adult patients who discontinued TKI outside studies, as
per clinical practice.
Methods
Study design and purpose
We designed a retrospective observational study of Italian
patients with Philadelphia positive (Ph+) CML in chronic phase
who had discontinued TKI treatment in DMR, with a follow up
after discontinuation over one year. All hematology centers
belonging to the Italian Group for the Hematologic Diseases of
the Adults (GIMEMA) were invited to participate; thirty-two
centers contributed to this study. The primary end point of the
study was the TFR rate after one year from TKI treatment dis-
continuation. Secondary end points included: longer-term TFR
status, safety (including the outcome after treatment resumption
and disease progression), identifying factors associated with
MR. Data on the main disease characteristics were collected for
each patient. These were: all treatments before and after discon-
tinuation, duration of each treatment,  response to each treat-
ment, and the reasons for discontinuation. The cutoff date for
this analysis was February 2017. The observational retrospective
study protocol was approved by the ethics committees of all
centers taking part. 
Response definitions and statistical analysis
Molecular response was assessed by quantitative polymerase
chain reaction (qPCR) according to the standard methodology;26
all analyses were performed by the GIMEMA Laboratories
Network (LabNet) for CML, expressed according to the
International Scale. Major molecular response (MMR) was defined
as a BCR-ABL1 ratio ≤0.1 with at least 10,000 ABL1 copies. Deep
molecular response was defined as MR4 (BCR-ABL1 ratio ≤0.01%
with at least 10,000 ABL1 copies), or MR4.5 (BCR-ABL1 ratio
≤0.0032% with at least 32,000 ABL1 copies), or MR5 (BCR-ABL1
ratio ≤0.001% with at least 100,000 ABL1 copies) confirmed at
least three times before TKI discontinuation.26 In a few patients
who discontinued TKI before the establishment of molecular stan-
dardization, DMR was defined as a level of BCR-ABL1 transcript
undetectable by qPCR or by qualitative PCR, confirmed in at least
two controls. The cytogenetic response was assessed according to
European LeukemiaNet (ELN) criteria.27 
Treatment-free response was assessed using the Kaplan-Meier
method, from the date of TKI discontinuation to the date docu-
menting the restart of therapy regardless of the reason. In fact,
since this is a retrospective study, criteria for treatment resumption
have not been pre-established. TFR was estimated using a Kaplan-
Meier curve and 95% confidence interval (CI). Deaths were con-
sidered as censored events. For all the other patients, data were
censored at the date of last qPCR. 
Continuous data were expressed as medians with interquartile
ranges (IQR, i.e. 25th and 75th percentiles) as a measure of variabil-
ity. A Mann-Whitney U test was used for comparison of quantita-
tive variables and χ2 or Fisher exact test was used for categorical
variables as appropriate. 
Clinical and biological variables at baseline were assessed as
potential independent prognostic factors for MR by univariate
analysis using Cox regression model. Variables were entered with-
out any transformation or cut off. 
For the multivariate analysis, a stepwise backward selection
procedure was carried out.28 The non-linear effect of continuous
covariates was modeled using a restrictive cubic spline function,
and its significance was assessed using the Wald test; similar
methods were used to check interactions.29 The best fitting model
was chosen according to the Akaike information criterion. 
P=0.05 was considered statistically significant. All analyses
were carried out using R v.3.3.3 statistical software.30
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161) overall estimated TFR was 62% (95%CI: 56;68). At 12 months, TFR was 68% (95%CI:  62;74) for ima-
tinib, 73% (95%CI:  64;83) for second generation TKI. Overall median time to restart treatment was six
months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study,
our experience within the Italian population confirms that discontinuation of imatinib and second generation
TKI is feasible and safe in clinical practice.
Results
Patients
We collected data on 293 patients who discontinued
TKI between June 2003 and February 2016. Overall, 34  of
293 patients (11.5%) suspended treatment because they
were enrolled in the prospective interventional Imatinib
Suspension and Validation (ISAV) study.13 All the other
patients discontinued as per clinical practice, and the rea-
sons were: toxicity (20%, 58 of 293), pregnancy (6%, 17
of 293), and a shared decision between the treating physi-
cian and the patient (62%, 182 of 293). Finally, one patient
discontinued the TKI because of chemotherapy for anoth-
er neoplasia. Reason of discontinuation was not known
for one patient. 
Patients’ characteristics are reported in Table 1. Median
age was 49 years (IQR 38-60) at diagnosis and 59 years
(IQR 48-70) at discontinuation. At the time of discontinu-
TKI discontinuation in CML clinical practice
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Table 1. Patients’ baseline characteristics.
                                                                                               Imatinib                 2nd generation TKI                  Overall                              P
N                                                                                                                      211                                         82                                        293                                         
Age at diagnosis (median [IQR])                                                     47 [36, 58]                          55 [45, 67]                         49 [38, 60]                              0.001
Age at discontinuation (median [IQR])                                          58 [46,67]                           63 [51, 74]                         59 [48, 70]                              0.023
Sex                                                                                                                                                                                                                                                        0.884
Males (%)                                                                                               117 (56)                               44 (54)                              161 (55)                                     
Sokal Score n=263 (%)                                                                                                                                                                                                                    0.346
Low                                                                                                          114 (61)                               40 (52)                              154 (59)                                     
Intermediate                                                                                           52 (28)                                 28 (36)                                80 (30)                                      
High                                                                                                           20 (11)                                  9 (12)                                 29 (11)                                      
Type of transcript n=252 (%)                                                                                                                                                                                                         0.126
b2a2                                                                                                           42 (23)                                 20 (29)                              62 (24.5)                                    
b2a3                                                                                                             0 (0)                                   1 (1.5)                                 1 (0.5)                                      
b3a2                                                                                                        141 (76.5)                              46 (68)                              187 (74)                                    
b3a3                                                                                                           1 (0.5)                                   0 (0)                                  1 (0.5)                                      
e1a2                                                                                                             0 (0)                                   1 (1.5)                                 1 (0.5)                                      
Last TKI (%) n=293                                                                                                                                                                                                                         <0.001
Imatinib                                                                                                  211 (100)                                 0 (0)                                 211 (72)                                     
Nilotinib                                                                                                     0 (0)                                   58 (71)                              58 (19.5)                                    
Dasatinib                                                                                                    0 (0)                                   23 (28)                                 23 (8)                                       
Bosutinib                                                                                                   0 (0)                                     1 (1)                                  1 (0.5)                                      
Line of treatment at discontinuation (%) n=293                                                                                                                                                                    <0.001
1st line                                                                                                      129 (61)                               33 (40)                              162 (55)                                     
2nd line                                                                                                     81 (38.5)                               36 (44)                              117 (40)                                     
3rd line                                                                                                       1 (0.5)                                 12 (15)                               13 (4.5)                                     
4th line                                                                                                         0 (0)                                     1 (1)                                  1 (0.5)                                      
Reasons for discontinuation (%) n=292                                                                                                                                                                                   <0.001
Shared decision                                                                                    135 (64)                               47 (57)                              182 (62)                                     
Toxicity                                                                                                    28 (13.5)                               30 (37)                                58 (20)                                      
ISAV13                                                                                                      34 (16)                                   0 (0)                                34 (11.5)                                    
Pregnancy                                                                                                 12 (6)                                    5 (6)                                   17 (6)                                       
Chemotherapy for 2nd tumor                                                             1 (0.5)                                   0 (0)                                  1 (0.5)                                      
MR at discontinuation (%) n=290                                                                                                                                                                                                 0.315
MR4                                                                                                           70 (33)                                 31 (38)                              101 (35)                                     
MR4.5                                                                                                        61 (29)                                 29 (36)                                90 (31)                                      
MR5                                                                                                           41 (20)                                 12 (15)                                53 (18)                                      
Transcript undetectable                                                                         37 (18)                                  9 (11)                                 46 (16)                                     
Duration of last TKI (median [IQR])                                             96 [62, 120]                         50 [32, 66]                        77 [54, 111]                           <0.001
Duration of treatment with any TKI (median [IQR])                96 [62, 120]                         73 [51, 98]                        87 [59, 117]                             0.002
Duration of total treatment (median [IQR])                              104 [73, 142]                       76 [52, 109]                       98 [65, 133]                           <0.001
Time to DMR (median [IQR])                                                          24 [12, 52]                           13 [6, 26]                          21 [10, 42]                            <0.001
Duration of DMR (median [IQR])                                                   53 [33, 82]                          36 [25, 46]                         46 [30, 73]                            <0.001
IQR: interquartile ranges; TKI: tyrosine kinase inhibitor; MR: molecular response; DMR: deep molecular response.
ation, 211 patients (72%) were on treatment with ima-
tinib and 82 patients (28%) with either nilotinib (n=58),
dasatinib (n=23), or bosutinib (n=1). There were no differ-
ences in age, sex, Sokal score and type of transcript
between imatinib and second generation TKI. One hun-
dred and sixty-two patients (55%) discontinued in first
line, 117 patients (40%) in second line, 13 patients (4.5%)
in third line, and one patient in fourth line. Among those
who discontinued imatinib, 73 patients (35%) had been
pre-treated with α-interferon (IFN) and seven patients had
been submitted to allogeneic stem cell transplantation.
Median duration of treatment with any TKI was 87
months (IQR 59-117) for all patients, 96 months (IQR 62-
120) for imatinib patients, and 73 (IQR 51-98) months for
second generation TKI patients (P=0.002). Median dura-
tion of treatment with the last TKI was 77 months (IQR
54-111) for all patients, and 50 months (IQR 32; 66) for
second generation TKI patients. Median duration of DMR
was 46 months (IQR 30-73) for all patients, 53 months
(IQR 33-82) for imatinib patients, and 36 months (IQR 25-
46) for second generation TKI patients (P<0.001). Overall,
all patients but one had an optimal early response to last
treatment. At three months of last TKI, 34% of patients
were in MMR, 40% were in CCyR and/or had a transcript
≤1%, and 25% were in PCyR and/or had a transcript
≤10%.
At treatment discontinuation the response was as fol-
lows: undetectable transcript in 16% of patients, MR4 in
35% of patients, MR4.5 in 31% of patients, and MR5 in
18%. There was no difference in the grade of molecular
response at discontinuation between patients on imatinib
and patients on second generation TKI (P=0.315). 
Relapses and treatment-free remission
At 12 months, the estimated TFR was 69% (95%CI: 64-
75) for all patients (Figure 1A), 68% (95%CI: 62-74) for
imatinib patients (Figure 1B), 73% (95%CI: 64-83) for sec-
ond generation TKI patients (Figure 1C). 
Median follow up was 34 months (IQR 24-53) for all
patients, 42 months (IQR 26-56) for imatinib patients, and
26 months (IQR 21-34) for second generation TKI
patients. At median follow up, TFR was 62% (95%CI: 56-
68) for all patients (at 34 months), 60% (95%CI: 54-67) for
imatinib patients (at 42 months), 67% (95%CI: 57-78) for
second generation TKI patients (at 26 months) (Figure 1).
There was no significant difference in TFR between
patients who had discontinued imatinib first-line versus
imatinib after IFN versus further lines (P=0.35), and there
was no difference in TFR between patients who discontin-
ued second generation TKI frontline (n=33) versus second-
line for intolerance (n=30) versus second-line for resistance
(n=16) (P=0.16). 
Overall, 114 patients (39%) resumed treatment.
Reasons for resuming were: loss of MR4 (19%), loss of
MMR (70%), loss of CCyR (9%), other (2%). The reasons
for restarting imatinib and second generation TKI were
similar  (P=0.13). Overall median time to restart treatment
was six months (IQR 4-11). Although 75% of patients had
restarted treatment by the end of the first year, the last
treatment resumption was after 105 months of TFR.
Median time to loss of MR4 was three months (IQR 2-7);
median time to loss of MMR was four months (IQR 3-7),
and median time to loss of CCyR was five months (IQR
4-6). Median time from loss of response to restarting treat-
ment was one month (IQR 0-2). 
C. Fava et al.
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Figure 1. Kaplan-Meier curves for Italian patients who discontinued tyrosine kinase inhibitor (TKI). (A) Overall population. (B)  Patients who discontinued imatinib.
(C) Patients who discontinued second generation TKI. Estimated treatment-free remission (TFR) is reported at 12 months for the overall population; at 12, 26 (medi-
an follow up for patients who discontinued second generation TKI), and 42 (median follow up for patients who discontinued imatinib) months for imatinib; at 12 and
26 months (median follow up for patients who discontinued second generation TKI) for second generation TKI. N: number.
A B
C
No progressions occurred. Nine deaths were reported
but none of them was disease related. 
The patients who resumed therapy (Table 2) were given
imatinib (n=77), nilotinib (n=22), dasatinib (n=9), bosu-
tinib (n=3), ponatinib (n=1), or IFN (n=2). Most of the
patients who stopped imatinib restarted imatinib after
relapse, and patients who were on second generation TKI
mainly stayed with second generation TKI.  Ninety-four
percent of the patients who were retreated achieved at
least another MMR, and 82% of them achieved another
DMR, fitting the criteria for a second attempt at discontin-
uation.31
In 20 patients who had lost MR4, and in four patients
who had lost MMR, the treatment was not resumed fol-
lowing a shared decision with the doctor. Interestingly,
they were still on the same response after a median time
of 12 months (IQR 1-32). 
Prognostic factors
Univariate analysis – Univariate analysis was used to
assess  age (considered as continuous variable), sex
(female vs. male), Sokal score (intermediate vs. low; high
vs. low), type of therapy (second generation TKI vs. ima-
tinib), line of therapy at stop (imatinib vs. imatinib post
IFN; first-line second generation vs. second  generation in
second or further lines), type of transcript (b2a2 vs. others),
duration of therapy with the last TKI and any TKI (contin-
uous variables), duration of total treatment (continuous
TKI discontinuation in CML clinical practice
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Table 2. Type of retreatment after failure of discontinuation.
                                                                                       Overall                              2nd generation TKI                                 Imatinib 
                                                                                       (n=114)                                       (n=26)                                            (n=88)
Type of retreatment (%)                                                                                                                                                                                                      
Imatinib                                                                                            77 (67)                                                   2 (8)                                                       75 (85)  
Nilotinib                                                                                          22 (19)                                                 18 (69)                                                       4 (5)
Dasatinib                                                                                          9 (8)                                                    4 (15)                                                        5 (6)
Bosutinib                                                                                          3 (3)                                                     1 (4)                                                         2 (2)
Ponatinib                                                                                          1 (1)                                                     1 (4)                                                         0 (0)
IFNα                                                                                                  2 (2)                                                     0 (0)                                                         2 (2)
Table 3. Hazard Ratios (HRs) computed at univariate analysis.
                                                                                                                            HR                                 95%CI                                            P
Sex                                                                                                                                                                                                                                                                  
female vs.male                                                                                                                       1.17                          0.81                           1.69                                    0.41
Sokal score                                                                                                                                                                                                                                                   
Intermediate vs. low                                                                                                              0.74                          0.47                           1.17                                    0.19
high vs. low                                                                                                                               1.66                          0.98                           2.81                                    0.06
Type of therapy                                                                                                                                                                                                                                            
2nd generation vs. imatinib                                                                                                    0.8                           0.52                           1.23                                    0.31
Type of transcript                                                                                                                                                                                                                                        
b2a2 vs. others                                                                                                                         0.93                          0.58                           1.49                                    0.77
Age at discontinuation (older vs. younger; diff. of 22 ys)                                               0.76                          0.58                           0.98                                    0.04
Duration of DMR* (diff. of 43 mos)                                                                                     1.01                          0.77                           1.31                                    0.97
Time to DMR before stop* (32 mos increase)                                                                 0.97                          0.75                           1.27                                    0.84
Duration of therapy with last TKI* (57 mos increase)                                                    1.04                          0.80                           1.37                                    0.73
Duration of treatment with any TKIs* (58 mos increase)                                             0.85                          0.64                           1.13                                    0.27
Duration of total treatment* (68 mos increase)                                                              0.79                          0.62                           1.02                                    0.07
Depth of MR at stop                                                                                                                                                                                                                                   
MR4.5 vs.MR4                                                                                                                           0.67                          0.42                           1.07                                     0.1
MR5 vs.MR4                                                                                                                             0.68                           0.4                            1.14                                    0.14
Undetectable vs.MR4                                                                                                             0.7                            0.4                            1.19                                    0.18
Line of therapy at stop                                                                                                                                                                                                                              
1st line vs. ≥ 2nd line                                                                                                                  1.53                          1.04                           2.24                                    0.03
Reason for discontinuation                                                                                                                                                                                                                      
Pregnancy vs. shared decision with MD                                                                              1.57                          0.81                           3.05                                    0.18
ISAV vs. shared decision with MD                                                                                         1.40                          0.82                           2.38                                    0.22
Toxicity vs.shared decision with MD                                                                                    0.73                          0.43                           1.21                                    0.22
*For each variable the difference of months between groups of patients considered for computing HR corresponds to the Interquartile Range (IQR); ys: years; DMR: deep 
molecular response; mos: months; MD: medical doctor.
variable), time to DMR and DMR duration (continuous
variables), depth of MR at stop (MR4.5 vs. MR4, MR5 vs.
MR4 and Undetectable vs. MR4), reasons for discontinua-
tion (pregnancy, ISAV study and toxicity vs. shared deci-
sion with medical doctor). The only statistically signifi-
cant risk factors that affected TFR were age at discontinu-
ation (with a higher risk for younger patients) and line of
treatment (Table 3). When we assessed the duration of
total treatment for patients who discontinued TKI in front
line versus second line, we observed that patients who dis-
continued treatment front line had a significantly shorter
duration of treatment (P<0.001) (Table 4). 
Multivariate analysis - The line of treatment lost statisti-
cal significance in a multivariate analysis including age at
discontinuation, Sokal score, duration of total treatment,
line of treatment, and type of TKI at discontinuation
(Table 5). Patients treated with second generation TKI
showed a better TFR (HR 0.43; 95%CI:  0.20-0.91) (Table
5 and Figure 2). Duration of total treatment was positively
associated with TFR among patients treated with second
generation TKI with a 22% risk reduction for one addi-
tional year of treatment (HR: 0.78; 95%CI: 0.65-0.93).
Discussion
Although at present no guidelines explicitly recommend
treatment discontinuation, this study showed that many
physicians have already experienced TKI cessation in their
clinical practice because of intolerance, toxicity, and
patient desire to stop the treatment. This multi-center
observational study has confirmed that treatment cessa-
tion was safe as no progression occurred and the overall
TFR was 69% at 12 months, consistent with data reported
in previous studies.6-25 After discontinuation, patients were
monitored with the same frequency as in the EURO-SKI
study: most of the patients had a molecular evaluation
every month for the first six months, every six weeks for
C. Fava et al.
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Figure 2. Tyrosine kinase inhibitor (TKI)-treatment-
free remission (TFR) curves adjusted for age at dis-
continuation, Sokal score, line of therapy, and dura-
tion of disease.  
Table 4. Median and Interquartile Range of duration of treatment in patients who discontinued treatment in first line or in second or further lines
of therapy. 
Lines of treatment at discontinuation                                    Duration of total treatment                                         P
                                                                                                        [median (IQR)]                                                    
1st Line                                                                                                                    82 (60; 105)                                                             <0.001
≥2nd Line                                                                                                               128 (86;169)                                                                  
IQR: Interquartile Ranges.
Table 5. Multivariate Cox regression analysis for restarting therapy. Figures reported are Hazard Ratios and 95% confidence intervals.
                                                                                                                                                       HR                         95%CI                        P
Age at discontinuation (10 yrs difference)                                                                                                          0.84                   0.73                 0.97                  0.02
Sokal score                                                                                                                                                                                                                                                   
Intermediate vs. low                                                                                                                                               0.92                   0.54                 1.57                  0.76
High vs. low                                                                                                                                                               2.07                   1.16                 3.71                  0.01
Line of therapy: 2nd  vs. 1st line                                                                                                                                   0.80                   0.50                 1.30                  0.37
2nd generation TKIs vs. imatinib                                                                                                                               0.43                   0.20                 0.91                  0.03
Duration of total therapy (one yr increase) in patients treated with imatinib*                                        1.00                   0.94                 1.07                  0.90
Duration of total therapy (one yr increase) in patients treated with 2nd generation TKIs**                  0.78                   0.65                 0.93                  0.01
*HR =1 expresses no risk increase associated to the increase of 1 year of the duration of therapy in patients treated with imatinib. ** HR < 1 expresses the risk reduction asso-
ciated to the increase of 1 year of the duration of therapy in patients treated with 2nd generation tyrosine kinase inhibitor (TKI); yr:  years; HR: Hazard Ratios; CI: Confidence
Intervals.
imatinib
2nd generation
the subsequent six months, and then every three
months.21 Although we may think that a stringent moni-
toring is protective, and indeed most of the relapses
occurred during the first year, late relapses were not com-
plicated by loss of complete hematologic remission or pro-
gression to advanced phases, even if monitoring was less
frequent.32 Given this, we must mention that Italian cen-
ters rely on the Lab-net CML network, which ensures a
standardized measurement of minimal residual disease,
with a short turn-around time between sampling and
reporting. 
The history of CML has been revolutionized by the
introduction of imatinib, and while this has resulted in an
extraordinary improvement in survival, second generation
TKI have refined our concept of CML. The achievement
of higher rates of DMR in shorter periods of time
switched the goal of CML treatment from survival to cure,
to the point that TFR was included in the data sheet of
nilotinib.33 However, for the moment, a definitive treat-
ment discontinuation is not yet an option for everybody.
All the studies have tried to define prognostic factors for a
successful TFR in order to increase the number of patients
who can experience a successful discontinuation. In our
study, having a high Sokal risk score at diagnosis was pre-
dictive for a worse outcome, in agreement with the STIM
and the Korean studies.7,16 As in the ISAV trial,13 we
showed that age might have a role in the maintenance of
response, with an advantage for older patients. We retro-
spectively observed that our population was almost
entirely characterized by an optimal early response at
three months; this  could explain why TFR was compara-
ble when discontinuation occurred in a first-line setting or
during subsequent lines of therapy. Duration of treatment
was reported as a prognostic factor in many studies.7,15,16,21
In our analysis, the duration of total treatment for patients
who discontinued TKI in second line was significantly
longer compared to patients who discontinued TKI in
front-line (128 vs. 82 months). This could possibly account
for the lower risk of relapses in patients who discontinued
TKI in second line as shown in the univariate analysis. In
fact, in the multivariate analyses, the line of treatment lost
significance. In our study, the total duration of treatment
had a positive influence particularly on patients treated
with second generation TKI: we observed a 22% reduc-
tion of the risk of resuming therapy per year of treatment. 
In this study, we observed that patients who discontin-
ued second generation TKI had a median duration of treat-
ment with the last TKI of 50 months versus 96 months of
treatment with imatinib (Table 1). The results are in line
with those of several prospective studies, such as  the
ENEST Freedom, the ENEStop (median duration of treat-
ment with nilotinib of 43 months and 53 months, respec-
tively), and the EURO-SKI trials (median duration of treat-
ment with imatinib of 91 months).20,21,25 Furthermore, the
multivariate Cox proportional hazards regression model
showed a better probability of TFR for patients treated
with second generation TKI, with an estimated 57% rela-
tive risk reduction in favor of the second generation TKI.
Even considering the quite large confidence interval, the
minimum risk reduction is still 9%. These data are in
keeping with the superiority of second generation TKI in
deeply and rapidly reducing the level of disease.
Importantly, almost all the patients who were retreated
regained at least MMR, and 82% regained the DMR crite-
ria for a second discontinuation attempt, which has been
recently proven to be feasible.31 In fact, Legros et al. report-
ed that 35% of patients who had a second discontinuation
attempt (median total time of treatment of 103 months)
remained free from relapse at three years.31 Those who
have eventually restarted treatment had nonetheless taken
advantage of a treatment 'holiday' without meaningful
risks.
Conclusions
This multicenter observational study included a sub-
stantial number of patients who were cared for in care
institutes through clinical practice procedures, confirming
that treatment discontinuation is safe and effective also
outside controlled clinical trials. Taking into account all
the evidence collected in the last ten years, we think that
TKI discontinuation in patients in persistent DMR must
be considered in routine clinical practice, as long as molec-
ular monitoring is performed regularly in standardized
laboratories, and in accordance with the criteria stated in
the ESMO and NCCN recommendations.34,35
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